Akoya Biosciences — Merger or Acquisition (April 2025)
53 slides from Akoya Biosciences's merger presentation, Apr 29, 2025
Slide 1: Amended Merger Agreement: Synergistic Combination
Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025
Slide 2: Legal Information
Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities and Exchange Commission (“SEC”) a post - effective amendment to it
Slide 3: Legal Information (Continued)
Legal Information (Continued) 3 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS Statements included in this presentation which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward - looking statements for purposes of the
Slide 4: Table of Contents
Table of Contents 4 5 Executive Summary I 15 The Combination Offers Stockholders the Greatest Opportunity for Value Creation II 37 The Amended Transaction Is the Result of a Rigorous Process Led by an Unconflicted Transaction Committee and an Independent Board of Directors III 46 Conclusion IV 49 Ap
Slide 5: I. Executive Summary
I. Executive Summary 5
Slide 6: Amended Transaction Overview
Amended Transaction Overview 6 Total consideration to be paid to AKYA stockholders is valued at approximately $66 million 1 under the amended terms AKYA stockholders to receive $0.38 in cash and 0.1461 QTRX shares per share of AKYA Consideration QTRX stockholders to own ~84% of combined entity, up f
Slide 7: Executive Summary: Best Opportunity for Value Creation
Executive Summary 7 The Combination Provides Stockholders the Best Opportunity for Value Creation ▪ The transaction brings together complementary offerings to establish a market leader with an integrated platform for identifying and measuring biomarkers across both blood and tissue ▪ The combination
Slide 8: Quanterix: Leader in Ultra-Sensitive Biomarker Detection
Quanterix Leader in Ultra - Sensitive Biomarker Detection 8 Publications Installed Base 2024 Revenue 2024 Non - GAAP Gross Margin 1 Differentiated technology Proven track record of operational discipline Early penetration in multi - billion diagnostics CLIA lab running validated neuro LDTs North Ame
Slide 9: Strong Track Record of Operational Execution
9 Strong Track Record of Operational Execution 7 consecutive quarters of double - digit growth CAGR of 14% 1 Quality, repeating customer base Increased from ~65% to ~80% 1 Successful execution of Fix, Innovate and Translate (FIT) program Increased from ~37% to ~55% 1,2 Resulting from optimized overa
Slide 10: Akoya Biosciences: Leading the Spatial Biology Revolution
Akoya Biosciences Leading the Spatial Biology Revolution 10 Publications Installed Base 2024 Revenue 2024 Non - GAAP Gross Margin 1 Established leader with largest installed base in its market Fastest and most robust platform for tissue biomarker detection Recurring revenue through reagents, softwar
Slide 11: The Combination Advances Quanterix's Growth Plan
The Combination Advances Quanterix’s Growth Plan 11 Grow Menu Expand into adjacencies Translate into AD Diagnostics • Extend lead position in neurology biomarkers • Launch first - of - its - kind, novel brain - derived and neuro - inflammatory markers • Extracellular Vesicle (EVs) biomarker detectio
Slide 12: The Combined Company Will Be Well Positioned for Growth
The Combined Company Will Be Well Positioned for Growth 12 Growth Scale Efficiency Acceleration Strong Runway 1. Management’s estimate; excludes Dx and CDx. 2. Year ended December 31, 2024. 3. Assumes that the deal closes in Q2 2025. Expecting attractive growth in a $5B 1 addressable market Combined
Slide 13: Analysts Are Supportive of the Strategic Merits
Analysts Are Supportive of the Strategic Merits of the Combination We continue to believe the Akoya transaction is an attractive opportunity for Quanterix to leverage its strong relationships in academic research and translational medicine for biomarker discovery in both blood and tissue .” March 24
Slide 14: Customers Are Also Supportive of the Combination
Customers Are Also Supportive of the Combination Jon Christopher Aster, MD, PhD Michael A. Gimbrone Jr., MD, Endowed Chair in Pathology Brigham and Women’s Hospital We at Dana Farber/Brigham and Women’s Cancer Center and MGB are very excited about the prospect of combining information from blood pla
Slide 15: II. The Combination Offers Stockholders the Greatest Opportunity for Value Creation
II. The Combination Offers Stockholders the Greatest Opportunity for Value Creation 15
Slide 16: The Combination Expands Market Potential, Improves Scale
The Combination Expands Market Potential, Improves Scale and Creates a More Durable Business ▪ The transaction unites two companies focused on different yet complementary aspects of biomarker detection, enabling Quanterix to address a broader range of customer needs through joint commercial infrastr
Slide 17: The Transaction Expands Quanterix's Addressable Market in Research
The Transaction Expands Quanterix’s Addressable Market in Research 17 Addition of cutting - edge spatial biology capabilities Technology portfolio addresses customer needs in high - growth markets in neurology, oncology and immunology Akoya’s position in oncology and immunology is complementary to Q
Slide 18: Expanded Addressable Market: Neurology
The Transaction Expands Quanterix’s Addressable Market | NEUROLOGY 18 01 Source: 2023 Alzheimer’s Disease Facts and Figures from Alzheimer's Association® Alzheimer Disease International (https:// www.alzint.org) Global societal cost of dementia in the WHO report “Global status report on the public h
Slide 19: Expanded Addressable Market: Immunology
The Transaction Expands Quanterix’s Addressable Market | IMMUNOLOGY 01 Mood disorder Immuno - oncology Asthma Infectious disease Neuro inflammation A D , M S , P D Arthritis Obesity Autoimmune disorder Inflammation related disorders Cytokine 4 - Plex Panels address translational research needs in in
Slide 20: Expanded Addressable Market: Oncology
The Transaction Expands Quanterix’s Addressable Market | ONCOLOGY 01 20 Accelerate entry into Oncology Protein based tests have become increasingly important in testing and monitoring, and multi - omics - based approaches hasten need Accelerating effort by measuring biomarkers as they first transiti
Slide 21: Quanterix and Akoya Uniquely Positioned to Accelerate New Tests
Quanterix and Akoya Are Uniquely Positioned to Accelerate New Tests 01 From identification of proteomic biomarkers to their detection Spatial detection and characterization of biomarkers Ultra - sensitive biomarker detection Technology From tissue to blood Tissue Blood Sample Addressing the largest
Slide 22: The Combination Unites Clinical and Anatomical Pathology
The Combination Unites Clinical and Anatomical Pathology… 01 x Liquid biopsy to tissue of origin x Choosing right treatment x Monitoring of tumor treatment x Continuous monitoring x Assess Minimum Residual Disease x Measure therapy efficacy x Fewer biopsies First integrated dashboard harmonizing pat
Slide 23: Which Will Create New Opportunities for Growth
…Which Will Create New Opportunities for Growth 01 Apply consumables product development engine to accelerate growth of new biomarker pairs across tissue and blood. Suite of synergistic biomarkers already in development Over the past 2 years, Quanterix grew reagents by 24% Replicate Quanterix’s Acce
Slide 24: Complementary Technology and Service Offerings Expand Commercial Reach
Quanterix and Akoya’s Complementary Technology and Service Offerings Expand Commercial Reach 01 Assay & Reagents Instruments Lab Testing Services HD - X SR - X SP - X Ultra - sensitive SIMOA instruments – Benchtop & Sample to Answer Catalog and custom assays in single - plex and multiplex formats CL
Slide 25: Opportunity to Expand into Oncology
The Combination Presents a Compelling Opportunity to Expand into Oncology 01 Best - in - class tissue and blood detection combination is expected to drive early detection and monitoring in Oncology … Quanterix has already begun developing these tests Tissue leaks biomarkers into blood in ultra - low
Slide 26: Akoya Has a Market Leading Business with Strong Margins
Akoya’s gross margins have historically been superior to Quanterix’s Quarterly Non - GAAP Gross Margin 1 Akoya Has a Market Leading Business with Strong Margins 49.8% 57.8% 53.4% 54.7% 51.2% 50.7% 57.7% 57.4% 51.5% 60.6% 62.7% 56.8% 58.6% 57.8% 62.3% 67.4% 1Q 2023 2Q 2023 3Q 2023 4Q 2023 1Q 2024 2Q
Slide 27: Akoya Is on a Path to Cash Flow Breakeven
Akoya’s LTM EBIT loss narrowed ~25% year - over - year in the fourth quarter of 2024 Akoya LTM EBIT ($M) 1 Akoya Is on a Path to Cash Flow Breakeven 02 27 1. Source: FactSet. ($66) ($68) ($69) ($64) ($56) ($56) ($48) ($44) ($41) 4Q 2022 1Q 2023 2Q 2023 3Q 2023 4Q 2023 1Q 2024 2Q 2024 3Q 2024 4Q 2024
Slide 28: Akoya's Prospects Compare Favorably to Peers
28 Akoya’s Prospects Compare Favorably to Peers Akoya’s top - line growth trajectory and gross margin profile are projected to be superior to peers 2024 - 2027E Consensus Revenue CAGR 1 2027E Consensus Gross Margin 1 1. Source: FactSet. Data as of April 25, 2025. Peer data refers to median. 2. Perfo
Slide 29: Scale Matters in the Life Sciences Tools Industry
29 Scale Matters in the Life Sciences Tools Industry 03 Scaled life sciences tools companies are generally rewarded with higher valuation multiples and have historically delivered superior returns Median EV/2025E Revenue Multiple of Life Sciences Tools Companies 1,2 Median Annualized Total Stockhold
Slide 30: The Combined Company Will Have Significant Scale
30 The Combined Company Will Have Significant Scale 03 The combination creates the opportunity for increased scale, a broader product portfolio and a faster path to cash flow breakeven 1. Source: FactSet and company filings. 2024 Pro Forma Revenue ($M) 1 $4,372 $611 $200 $174 $154 $137 $82 $14 $3 $0
Slide 31: Opportunity for Significant Cost Savings
31 The Transaction Provides an Opportunity for Significant Cost Savings 04 Target for Full Year 2026 Target in First 12 Months $4M ~$2M ▪ Located near each other in the Boston area ▪ Have similar operating infrastructure ▪ Use nearly identical tools and antibodies / reagents ▪ Familiarity with Akoya
Slide 32: Clear Line of Sight to Anticipated Cost Savings
32 1. Based on combined 2024 operating expenses of $230.3 million, as disclosed in Quanterix’s and Akoya’s Form 10 - Ks, both of which were filed with the SEC on March 17, 2025. We Have a Clear Line of Sight to Achieving Anticipated Cost Savings 04 ▪ We identified significant cost savings opportunit
Slide 33: Continued Investment in Alzheimer's Disease Testing
33 Quanterix Is Expected to Be Well Positioned to Continue to Invest in Alzheimer’s Disease Testing, a ~$10B Market 05 Ongoing trials BioHermes II 100% enrollment Q4 2025 Davos Mt Sinai 100% enrollment Q3 2025 Davos VUMC 100% enrollment Q4 2025 CANTATE Phase II 100% enrollment Q4 2025 $20 Million in
Slide 34: Well Positioned to Navigate NIH Funding Uncertainty
34 The Combined Company Is Expected to Be Well Positioned to Navigate National Institutes of Health (NIH) Funding Uncertainty 05 The combined company is expected to have significantly more gross profit dollars not tied to NIH funding than standalone Quanterix, which we believe will provide stability
Slide 35: The Combined Entity Will Be More Compelling than Standalone
35 The Combined Entity Will Be More Compelling than Standalone 1. Based on 2024 revenue. 2. Management’s estimate; excludes Dx and CDx. 3. Based on $292 million in cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 and anticipated cash usage in 2025 of $60 mill
Slide 36: Combined Entity More Compelling than Standalone (Continued)
36 The Combined Entity Will Be More Compelling than Standalone (Continued) 05 +129% 2,365 1,330 1,035 Instrument Installed Base Larger Customer Footprint and Addressable Market +54% 4,933 1,733 3,200 Cumulative Publications +400% $5,000 $4,000 $1,000 Addressable Market – Research ($M) +70% $17,000 $
Slide 37: III. The Amended Transaction Is the Result of a Rigorous Process
III. The Amended Transaction Is the Result of a Rigorous Process Led by an Unconflicted Transaction Committee and an Independent Board of Directors 37
Slide 38: Quanterix's Board of Directors Is Experienced and Independent
▪ The process was led by an independent Board and an unconflicted Transaction Committee comprised of experienced directors with deep knowledge of diagnostics, life sciences, M&A transactions, strategic partnerships and financings ▪ All directors understand and embrace their fiduciary duties to Quant
Slide 39: Quanterix Board Member Profiles
39 Masoud Toloue, PhD Chief Executive Officer Director since 2022 ▪ Scaled PerkinElmer’s Diagnostics division to over 50% of the Company’s revenue as SVP, Diagnostics ▪ Founded and led Bioo Scientific’s next - generation sequencing business until its acquisition by PerkinElmer ▪ Co - founded Genohub
Slide 40: The Board's Disciplined, Responsive and Engaged Approach
The Board’s disciplined, responsive and engaged approach has resulted in a compelling transaction for Quanterix stockholders From time to time, the Board has considered certain strategic alternatives; in 2023, it formed a dedicated Transaction Committee which, among other alternatives, identified Ak
Slide 41: Why Quanterix Does Not Share Those Concerns
Why Quanterix Does Not Share those Concerns Party’s Expressed Concerns Party Quanterix has ample cash to repay Akoya’s debt without materially impairing its balance sheet, and the acquisition is expected to accelerate Quanterix’s ability to generate cash Party B had a different view than Quanterix w
Slide 42: The Amended Transaction Is Attractive in Light of Industry Headwinds
42 The Amended Transaction Is Attractive in Light of Industry Headwinds C Indexed Price of Performance Peers Since Initial Merger Consideration per Akoya Share 1 Transaction Announcement 1,2 Market dislocation driven by NIH funding concerns and general macroeconomic uncertainty… …led the Board to re
Slide 43: Implied Value of Proposals Declined Over Time
The Implied Value of Our Proposals Declined Over Time, Reflecting the Board’s Ability to Negotiate a Favorable Initial Transaction C Even though Quanterix was in a competitive bidding process, the Board negotiated a favorable exchange ratio that valued Akoya at approximately $0.12 per share lower th
Slide 44: Evolution of Quanterix Proposals
Evolution of Quanterix Proposals 1 The Amended Transaction Is Markedly Better than the Initial Transaction C The Board reengaged with Akoya and renegotiated the transaction in a manner that is favorable to Quanterix stockholders $3.38 44 1. Source: Quanterix Form S - 4/A, filed with the SEC on April
Slide 45: Implied Transaction Multiple Compares Favorably to Precedent Transactions
The implied transaction multiple for Akoya is the lowest among comparable life sciences transactions over the last few years EV/LTM Revenue Multiple at Announcement 1 The Implied Transaction Multiple Compares Favorably to Precedent Transactions at Announcement C 45 1. Source: FactSet and company fil
Slide 46: IV. Conclusion
IV. Conclusion 46
Slide 47: The Combined Company Will Be Uniquely Positioned to Deliver Value
The Combined Company Will Be Uniquely Positioned to Deliver Value 47 Significant cost savings across operations and SG&A Expanded customer relationships & continuum of solution offerings maximize cross - selling opportunities Creates first integrated platform of liquid and tissue biomarkers Unlocks
Slide 48: Conclusion: Best Opportunity for Value Creation
Conclusion The Combination Provides Stockholders the Best Opportunity for Value Creation ▪ The transaction brings together complementary offerings to establish a market leader with an integrated platform for identifying and measuring biomarkers across both blood and tissue ▪ The combination position
Slide 49: V. Appendix
V. Appendix 49
Slide 50: Reconciliation of Quarterly GAAP to Non-GAAP Measures – Quanterix
Three Months Ended December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 (Amounts in millions except percentages) $22.2 $20.2 $22.2 $18.5 $19.4 $19.4 $19.4 $16.0 Gross profit ($1.9) ($2.0) ($2.1) ($2.1) ($2.1) ($2.6) ($1.6
Slide 51: Reconciliation of Quarterly GAAP to Non-GAAP Measures – Akoya
Three Months Ended December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 (Amounts in millions except percentages) $14.4 $11.7 $13.4 $8.4 $16.6 $15.3 $12.1 $12.3 Gross profit - - - $2.0 - - - - Plus : Provision for excess a
Slide 52: Reconciliation of Annual GAAP to Non-GAAP Measures – Quanterix
Reconciliation of Annual GAAP to Non - GAAP Measures – Quanterix 1. Gross profit as a percentage of total revenues. 2. Non - GAAP gross profit as a percentage of total revenues. 52 Year Ended December 31, 2024 Year Ended December 31, 2022 (Amounts in millions except percentages) $83.1 $46.8 Gross pr
Slide 53: Reconciliation of Annual GAAP to Non-GAAP Measures – Quanterix and Akoya
53 1. Gross profit as a percentage of total revenues. 2. Non - GAAP gross profit as a percentage of total revenues. 3. Non - GAAP gross profit from U.S. academic customers used as a proxy for NIH - funded non - GAAP gross profit. Reconciliation of Annual GAAP to Non - GAAP Measures – Quanterix and A
Akoya Biosciences — Merger or Acquisition (April 2025) on 6ix